Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00067080
Recruitment Status : Completed
First Posted : August 13, 2003
Last Update Posted : August 22, 2017
Information provided by:

Brief Summary:
The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.

Condition or disease Intervention/treatment Phase
Anemia, Sickle Cell Drug: ICL670, deferoxamine Phase 2

Detailed Description:
Patients who require repeated blood transfusions accumulate iron in the body as blood cells contain iron and there is no natural body mechanism to eliminate it. After a while the iron levels get high enough to be toxic to the body. The current therapy of choice is deferoxamine which does a good job of removing excess iron, but is difficult to administer. Deferoxamine requires subcutaneous (under the skin) infusions over 4 to 8 hours nightly 3 to 7 nights per week. In addition to the need to wear an infusion pump nightly, adverse reactions around the site of the injection are frequent.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis
Study Start Date : May 2003
Actual Primary Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron
U.S. FDA Resources

Arm Intervention/treatment
Experimental: ICL670 + deferoxamine Drug: ICL670, deferoxamine
Other Name: deferasirox

Primary Outcome Measures :
  1. Evaluate the safety and tolerability of multiple doses of ICL670 [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Estimate the absolute and relative change of liver iron content (LIC) and total body iron excretion (TBIE) [ Time Frame: at baseline, after 24 weeks and at 1year (end of study) ]
  2. Evaluate the pharmacokinetics [ Time Frame: 24 hours post-dose @ 4, 12, 24 and 52 weeks ]
  3. Evaluate the relationship between pharmacokinetics, pharmacodynamics and safety variables [ Time Frame: at 24 and 52 weks pre-dose ]
  4. Evaluate the relationship between hepatic iron and potential surrogate markers [ Time Frame: at screen, at washout, then every 2 weeks for the first 12 weeks followed by every 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age greater than or equal to 2 years
  • Sickle cell disease patients already treated with or suitable for treatment with deferoxamine 20 to 40 mg/kg/day
  • Serum ferritin greater than 1000 mg/ml
  • Liver iron content greater than 2 mg iron/g dw assessed by means of superconducting quantum interference device (SQUID) for patients who receive simple transfusions and greater than 5 mg iron/ g dw for patients who receive exchange transfusions or who have a history of intermittent blood transfusion.
  • Regular transfusion aimed at maintaining % Hb A above 50% or a previous history of simple transfusion being the recipient of at least 20 units of packed red blood cells.

Exclusion Criteria:

  • Chronic anemias other than sickle cell disease
  • Documented toxicity to deferoxamine
  • Elevated liver enzymes in the year preceeding enrollment
  • Active hepatitis B or hepatitis C
  • HIV seropositivity
  • Elevated serum creatinine or significant proteinuria
  • History of nephrotic syndrome
  • Uncontrolled systemic hypertension
  • Fever and other signs/symptoms of infection within 10 days prior to the start of the study
  • Presence of clinically relevant cataract or previous history of clinically relevant ocular toxicity related to iron chelation
  • Second or third degree AV block, clinically relevant Q-T interval prolongation, or patients requiring digoxin or other drugs that prolong the Q-T interval (other than beta-adrenergic receptor blocking agents).
  • Diseases (cardiovascular, renal, hepatic, etc.) that would prevent the patient from undergoing any of the treatment options
  • Psychiatric or addictive disorders that would prevent the patient from giving informed consent
  • History of drug or alcohol abuse within the 12 months prior to the study
  • Pregnant or breast feeding patients
  • Patients treated with systemic investigational drugs within 4 weeks or topical investigational drugs within 7 days before the start of the study
  • Patients who require concomitant therapy with hydroxyurea
  • Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug, such as gastrointestinal disease or major surgery, renal disease, difficulty voiding or urinary obstruction, or impaired pancreatic function
  • Non-compliant or unreliable patients
  • Patients unable to undergo any study procedures such as the hearing or eye tests, or the liver echocardiography
  • Patients unable to undergo SQUID examination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00067080

  Hide Study Locations
United States, Alabama
U. of S. Alabama Medical Center
Mobile, Alabama, United States, 36604
United States, California
Loma Linda University Medical Center
Loma Linda, California, United States, 92354
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Children's Hospital & Research Center
Oakland, California, United States, 94609
United States, Colorado
Colorado Sickle Cell Treatment and Research Center
Denver, Colorado, United States, 80262
United States, District of Columbia
Howard University Hospital
Washington, D.C., District of Columbia, United States, 20059
United States, Florida
Tampa Children's Hospital at St Joseph's
Tampa, Florida, United States, 33607
United States, Georgia
Georgia Comprehensive Sickle cell Center, Grady Hospital
Atlanta, Georgia, United States, 30335
Adult Sickle Cell Clinic, Medical College of Georgia
Augusta, Georgia, United States, 30912
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
United States, Louisiana
Tulane University Sickle Cell Center
New Orleans, Louisiana, United States, 70112
Children's Hospital, Department of Hematology/Oncology
New Orleans, Louisiana, United States, 70118
United States, Massachusetts
Children's Hospital Boston, Division of Hematology/Oncology
Boston, Massachusetts, United States, 02115
Boston Medical Center
Boston, Massachusetts, United States, 02118
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, New York
NY Methodist Hospital
Brooklyn, New York, United States, 11215
Weill Medical College of Cornell University
New York, New York, United States, 10021
U. Of Rochester Medical Center
Rochester, New York, United States, 14642
Sickle Cell Center, Montefiore Hospital
The Bronx, New York, United States, 10467
United States, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States, 27106
United States, Ohio
Barrett Center, University of Cincinnati
Cincinnati, Ohio, United States, 45219
Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
James Cancer Hospital
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Liberty Hematology Oncology Center
Columbia, South Carolina, United States, 29203
Palmetto Health Clinical Trials
Columbia, South Carolina, United States, 29203
Santee Hematology/Oncology
Sumter, South Carolina, United States, 29150
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Texas Children's Hospital/Baylor College of Medicine
Houston, Texas, United States, 77030
Scott and White Memorial Hospital & Clinics
Temple, Texas, United States, 76508
United States, Virginia
Children's Hospital of the King's Daughter
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Additional Information:
Publications of Results:
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00067080     History of Changes
Other Study ID Numbers: CICL670A0109
First Posted: August 13, 2003    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: August 2017

Keywords provided by Novartis:
Sickle cell disease
iron overload

Additional relevant MeSH terms:
Anemia, Sickle Cell
Iron Overload
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Iron Metabolism Disorders
Metabolic Diseases
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action